Research shows women lose more weight than men on GLP-1s and have more side effects. Learn about other differences in GLP-1 ...

Weight-loss injections, such as Wegovy and Mounjaro, have transformed how we treat obesity. Around 1.6 million adults in ...

Emerging research shows that some people are 'super-responders' to GLP-1 drugs. Others don't respond at all. There is emerging research showing that some people are "super-responders" to GLP-1 ...

After losing its market edge to Eli Lilly (NYSE: LLY) despite its first-mover advantage in weight-loss drugs, Novo Nordisk is ...

The real goal is to lose excess fat while protecting muscle, strength, joint health, posture, balance, and metabolism.

Phase 3 interim results at 72 weeks showed semaglutide plus lifestyle achieved MASH resolution without fibrosis worsening in 63% versus 34% with placebo plus lifestyle. Preclinical MASH models ...

In 2024, Novo Nordisk was Europe’s most valuable company. Its blockbuster drugs used for weight loss, Ozempic and Wegovy, ...

Online health and wellness company Hims & Hers posted a $92 million loss in the first quarter as it shifts its business from selling compounded weight loss drugs to branded GLP-1 medications. During ...

Hers is a telehealth platform offering GLP-1 weight loss medications. Learn about its costs, pros, cons, and if it's right for you.

Side effects like nausea, vomiting, diarrhea and constipation are common soon after starting GLP-1s or increasing the drug’s dosage. A nutrient-dense diet and regular exercise a ...

Today, however, a new growth catalyst has emerged, and it's the GLP-1 pill. Both companies recently won approval for their ...